SCHEMBL14745487

SCHEMBL14745487

Cn1ccc2cc(-c3nc(OCc4ccccc4)c(C(=O)OCc4ccccc4)c(OCc4ccccc4)c3O)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.38
HSD11B1 P28845 1/20 0.38
JMJD6 Q6NYC1 1/20 0.37
LMNA P02545 3/20 0.36
HPGD P15428 2/20 0.36
CNR1 P21554 1/20 0.36
JAK2 O60674 2/20 0.35
KDM4E B2RXH2 2/20 0.35
GAA P10253 2/20 0.35
ALDH1A1 P00352 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MCL1 Q07820 2/20 0.35
SRD5A2 P31213 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
PDE1C Q14123 1/20 0.35
CCNC P24863 1/20 0.35
CDK8 P49336 1/20 0.35
NOTUM Q6P988 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14744834 0.90 FAAH (0.38) FAAHHSD11B1JMJD6LMNAHPGD
SCHEMBL17597416 0.84 CTSA (0.38) JMJD6LMNAHPGDCNR1JAK2
SCHEMBL16441034 0.83 HSD11B1 (0.41) FAAHHSD11B1SMN1; SMN2MCL1SRD5A2
SCHEMBL14745654 0.83 CNR1 (0.41) FAAHHSD11B1LMNAHPGDCNR1
SCHEMBL14758307 0.80 EGFR (0.40) HSD11B1CNR1CCNCCDK8
SCHEMBL17495025 0.77 JMJD6 (0.35) JMJD6LMNAHPGDCNR1KDM4E
SCHEMBL14745761 0.76 PIK3CD (0.42) JMJD6LMNACNR1JAK2KDM4E
SCHEMBL17494920 0.75 JMJD6 (0.33) JMJD6LMNAHPGDCNR1JAK2
SCHEMBL14741073 0.74 ADORA3 (0.46) LMNAHPGDCNR1MAPTPPARG
SCHEMBL16441035 0.73 KCNA3 (0.42) FAAHHSD11B1SRD5A2NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP FAAH 4028/4885HSD11B1 4432/4885JMJD6 2958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.